The public float for TELO is 17.03M, and currently, shorts hold a 0.09% of that float. The average trading volume for TELO on April 23, 2024 was 74.37K shares.
TELO) stock’s latest price update
Telomir Pharmaceuticals Inc (NASDAQ: TELO) has seen a decline in its stock price by -29.81 in relation to its previous close of 7.99. However, the company has experienced a -36.60% decline in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-04-02 that Telomir’s pre-clinical studies demonstrate its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase
TELO’s Market Performance
The volatility ratio for the week is 19.18%, and the volatility levels for the past 30 days are at 16.92% for TELO. The simple moving average for the past 20 days is -19.25% for TELO’s stock, with a -25.33% simple moving average for the past 200 days.
TELO Trading at -25.33% from the 50-Day Moving Average
After a stumble in the market that brought TELO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.95% of loss for the given period.
Volatility was left at 16.92%, however, over the last 30 days, the volatility rate increased by 19.18%, as shares sank -13.56% for the moving average over the last 20 days.
During the last 5 trading sessions, TELO fell by -36.54%, in comparison to the 20-day moving average, which settled at $6.90. In addition, Telomir Pharmaceuticals Inc saw 12.10% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TELO starting from Bay Shore Trust, who purchase 138,000 shares at the price of $7.00 back on Feb 13 ’24. After this action, Bay Shore Trust now owns 5,455,431 shares of Telomir Pharmaceuticals Inc, valued at $966,000 using the latest closing price.
Stock Fundamentals for TELO
Equity return is now at value -1045.36, with -542.12 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.10.
Conclusion
In conclusion, Telomir Pharmaceuticals Inc (TELO) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
